Crossmark

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma

Crossref DOI link: https://doi.org/10.1007/s00432-024-05795-2

Published Online: 2024-06-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, Yan-Song

Li, Shuo

Yang, Xia

Guo, Rong-Ping

Huang, Yu-Hua

Bai, Kun-Hao

Weng, Jun

Yun, Jing-Ping
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82072611, 82103220, 82273046)
License Information

Text and Data Mining valid from 2024-06-18

Version of Record valid from 2024-06-18
More Information

Article History

Received: 7 April 2024

Accepted: 9 May 2024

First Online: 18 June 2024

Declarations

:

: The authors declare no conflict of interest.

: Approval for the study was granted by the Institutional Review Board of Sun Yat-sen University Cancer Center (Approval No.: B2023-616-01).

: Written informed consent for treatment participation was obtained from all enrolled patients.

: The authors affirm that human research participants provided informed consent for publication of all images.

Document is current

Any future updates will be listed below